Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?

References

• Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 infection taking ACEI/ARB. Curr Cardiol Rep. 2020;22:31. doi:10.1007/s11886-020-01291-4.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, Lu M, Dittmer U, Yang D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARSCoV, MERS-CoV, and 2019- nCoV. J Med Virol. 2020;92:491–94. doi:10.1002/jmv.25709.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virology. 94; published online 2020 Jan 29. doi:10.1128/JVI.00127-20.
   Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–54. doi:10.1038/nature02145.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–69. doi:10.1001/jama.2020.1585.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–79.
   PubMed Web of Science ®Google Scholar
• Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30(3):160–64. doi:10.1016/j.tcm.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Morra ME, Van Thanh L, Kamel MG, Ghazy AA, Altibi AMA, Dat LM, Thy TNX, Vuong NL, Mostafa MR, Ahmed SI, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. Rev Med Virol. 2018;28:e1977.
   PubMed Web of Science ®Google Scholar
• Matsuyama R, Nishiura H, Kutsuna S. Hayakawa K and Ohmagari N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health. 2016;16:1203. doi:10.1186/s12889-016-3881-4.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B. Pons H and Johnson RJ. Role of the immune system in hypertension. Physiol Rev. 2017;97:1127–64. doi:10.1152/physrev.00031.2016.
   PubMed Web of Science ®Google Scholar
• Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16:491–502. doi:10.1038/s41569-019-0176-3.
   PubMed Web of Science ®Google Scholar
• Gheblawi M, Wang K, Viveiros A,  Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126:1456‐1474. doi: 10.1161/CIRCRESAHA.120.317015.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020;157:104833. doi:10.1016/j.phrs.2020.104833.
   PubMed Web of Science ®Google Scholar
• Igase M, Kohara K, Nagai T. Miki T and Ferrario CM. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res. 2008;31:553–59. doi:10.1291/hypres.31.553.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605‐2610. doi:10.1161/CIRCULATIONAHA.104.510461.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;e201624.
   Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L,  et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671–1681.
   Web of Science ®Google Scholar
• HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
   Google Scholar
• International Society of Hypertension. A statement from the international society of hypertension on COVID-19. 2020. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/
   Google Scholar